1. Show article details.

    BRIEF-Lilly And Incyte Announce Positive Top-Line Results From The North American Phase 3 Study Of Oral Selective JAK Inhibitor Baricitinib In Patients With Moderate- To Severe Atopic Dermatitis

    Reuters – 6:33 PM ET 02/11/2020

    Incyte Corp (INCY): * LILLY AND INCYTE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM THE NORTH AMERICAN PHASE 3 STUDY OF ORAL SELECTIVE JAK INHIBITOR BARICITINIB IN PATIENTS WITH MODERATE- TO SEVERE ATOPIC DERMATITIS. * Incyte Corp (INCY) - STUDY MET PRIMARY ENDPOINT OF AT LEAST 75% IMPROVEMENT OF SKIN INFLAMMATION AND KEY SECONDARY ENDPOINTS.

  2. Show article details.

    BRIEF-Health Canada Has Approved Taltz For The Treatment Of Active Ankylosing Spondylitis

    Reuters – 6:54 AM ET 02/11/2020

    Eli Lilly and Co (LLY): * HEALTH CANADA HAS APPROVED TALTZ® FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS. * ELI LILLY CANADA SAYS HEALTH CANADA APPROVED TALTZ ON FEB 4, 2020, FOR TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS Source text for Eikon: Further company coverage:

  3. Show article details.

    Lilly, Roche Drugs Fail to Halt Inherited Form of Alzheimer's -- 2nd Update

    DJ Business News – 4:22 PM ET 02/10/2020

    In the latest failed attempt to help people with Alzheimer's, a study found that experimental drugs from Eli Lilly& Co. and Roche Holdings AG failed to help people with a rare, inherited form of the dementia-causing disease. The negative outcome continues a long streak of studies in which experimental drugs fail to slow, halt or reverse the underlying worsening of Alzheimer's disease. Current treatments for Alzheimer's only temporarily alleviate symptoms but can't halt the...

  4. Show article details.

    US STOCKS-S&P 500, Nasdaq reach record closing highs; Chinese workers return

    Reuters – 4:19 PM ET 02/10/2020

    * Amazon (AMZN), Microsoft (MSFT), Alphabet lead indexes higher. * Tesla gains after Shanghai factory resumes production. * Simon Properties to buy Taubman Centers (TCO) for $3.6 bln. * Indexes up: Dow 0.60%, S&P 0.73%, Nasdaq 1.13% By Stephen Culp.

  5. Show article details.

    Lilly, Roche Drugs Fail to Halt Inherited Form of Alzheimer's -- Update

    DJ Business News – 3:39 PM ET 02/10/2020

    In the latest failed attempt to help people with Alzheimer's, a study found that experimental drugs from Eli Lilly& Co. and Roche Holdings AG failed to help people with a rare, inherited form of the dementia-causing disease. The negative outcome continues a long streak of studies in which experimental drugs fail to slow, halt or reverse the underlying worsening of Alzheimer's disease. Current treatments for Alzheimer's only temporarily alleviate symptoms but can't halt the...

  6. Show article details.

    US STOCKS-Nasdaq hits new high as investors look beyond coronavirus

    Reuters – 2:23 PM ET 02/10/2020

    * Amazon (AMZN), Microsoft (MSFT), Alphabet lead indexes higher. * Tesla gains after Shanghai factory resumes production. * Simon Properties to buy Taubman Centers (TCO) for $3.6 bln. * Indexes up: Dow 0.14%, S&P 0.26%, Nasdaq 0.61% By Stephen Culp.

  7. Show article details.

    US STOCKS-Wall Street higher on U.S. growth optimism; Nasdaq hits record

    Reuters – 12:05 PM ET 02/10/2020

    * Tech stocks provide biggest boost to S&P, Nasdaq. * Apple (AAPL) slips as China business shutdown threatens demand. * Tesla jumps after Shanghai factory resumes production. * Indexes up: Dow 0.28%, S&P 0.36%, Nasdaq 0.62% By Medha Singh.

  8. Show article details.

    Lilly, Roche Drugs Fail to Stymie Inherited Form of Alzheimer's

    DJ Business News – 11:12 AM ET 02/10/2020

    In the latest failed attempt to help people with Alzheimer's disease, a study found that experimental drugs from Eli Lilly& Co. and Roche Holdings AG failed to help people with a rare, inherited form of the dementia-causing disease. The negative outcome continues a long streak of studies in which experimental drugs fail to slow, halt or reverse the underlying worsening of Alzheimer's disease. Current treatments for Alzheimer's only temporarily alleviate symptoms but can't...

  9. Show article details.

    US STOCKS-Wall St steady as investors weigh coronavirus risks

    Reuters – 10:31 AM ET 02/10/2020

    * Apple (AAPL) slips as China business shutdown threatens demand. * Tesla jumps after Shanghai factory resumes production. * Indexes up: Dow 0.18%, S&P 0.18%, Nasdaq 0.36% By Medha Singh. Feb 10 - U.S. stocks ticked higher on Monday, as people returned to work in China after an extended new year holiday triggered by the coronavirus outbreak but sentiment remained fragile.

  10. Show article details.

    Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY™ (Pemetrexed for Injection)

    Business Wire – 9:54 AM ET 02/10/2020

    -- Eagle has exclusive rights to commercialize product for four months beginning February 1, 2022 -- Eagle Pharmaceuticals, Inc. (EGRX) today announced that it has received final approval from the U.S. Food and Drug Administration for its novel product, PEMFEXY™, a branded alternative to ALIMTA®. “We are pleased to receive final approval from FDA and look forward to making PEMFEXY available to the pat...

  11. Show article details.

    US STOCKS-Wall Street set for subdued open as investors weigh coronavirus risks

    Reuters – 8:55 AM ET 02/10/2020

    * Apple (AAPL) slips as China business shutdown threatens demand. * Tesla jumps after Shanghai factory resumes production. * Futures: Dow dips 0.08%, S&P flat, Nasdaq up 0.05% By Medha Singh.

  12. Show article details.

    Lilly's stock falls on failed Alzheimer's study

    MarketWatch – 8:01 AM ET 02/10/2020

    Shares of Eli Lilly and Co. (LLY) fell 4% in premarket trading on Monday after solanezumab, the experimental therapy it was testing in people with a form of Alzheimer's disease caused by a rare gene mutation, failed in a Phase 2/ 3 clinical study. Lilly said it does not plan to submit the experimental therapy to regulators for approval based on the primary endpoint studied in the trial. The results did not surprise analysts.

  13. Show article details.

    Roche, Lilly drugs fail to halt gene-driven Alzheimer's disease

    Reuters – 6:37 AM ET 02/10/2020

    * Study fails in inherited form of Alzheimer's. * Roche, Eli Lilly (LLY) said additional trials to continue. * 100s of Alzheimer's drug trials have failed. By John Miller. Experimental drugs from Roche and Eli Lilly (LLY) failed to halt Alzheimer's disease in their latest test, the companies said on Monday, in a blow to people whose genes make them particularly vulnerable to the illness.

  14. Show article details.

    BRIEF-Eli Lilly And Dian-Tu Platform Trial Is A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study

    Reuters – 2:06 AM ET 02/10/2020

    Eli Lilly and Co (LLY): * TOPLINE RESULTS FOR SOLANEZUMAB FROM DOMINANTLY INHERITED ALZHEIMER NETWORK TRIALS UNIT STUDY. * STUDY SHOWED THAT SOLANEZUMAB DID NOT MEET PRIMARY ENDPOINT. * ADDITIONAL ANALYSES OF SECONDARY ENDPOINTS AND BIOMARKERS ARE ONGOING BY WASHINGTON UNIVERSITY AND LILLY.

  15. Show article details.

    Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study

    PR Newswire – 1:00 AM ET 02/10/2020

    INDIANAPOLIS, Feb. 10, 2020  Eli Lilly and Company (LLY) today announced that the analysis performed by Washington University School of Medicine in the Dominantly Inherited Alzheimer Network Trials Unit Study showed that solanezumab did not meet the primary endpoint. "We are grateful to the courageous participants, their families, and clinical investigators for their dedication to the study.

  16. Show article details.

    Lilly to Participate in Guggenheim Healthcare Talks Idea Forum

    PR Newswire – 2:00 PM ET 02/07/2020

    INDIANAPOLIS, Feb. 7, 2020  Eli Lilly and Company (LLY) will participate in the Guggenheim Healthcare Talks Idea Forum on Thursday, February 13, 2020.

  17. Show article details.

    Eli Lilly prices migraine therapy at $640 for pack of eight pills

    Reuters – 10:52 AM ET 01/31/2020

    - Eli Lilly and Co (LLY) on Friday priced its acute migraine treatment at $640 for a pack of eight pills and said it will be made available in pharmacies in the next few days. The list price of a drug is not necessarily what patients actually pay.

  18. Show article details.

    Eli Lilly prices migraine therapy at $640 for pack of 8 pills

    Reuters – 10:45 AM ET 01/31/2020

    Eli Lilly and Co (LLY) on Friday priced its acute migraine treatment at $640 for a pack of eight pills and said it will be made available in pharmacies in the next few days. The list price of a drug is not necessarily what patients actually pay.

  19. Show article details.

    Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription

    PR Newswire – 10:43 AM ET 01/31/2020

    INDIANAPOLIS, Jan. 31, 2020  Eli Lilly and Company announced today that REYVOW™ C-V 50 mg and 100 mg tablets, an oral medication for the acute treatment of migraine with or without aura in adults, is now available for prescription and will be available in pharmacies in the next few days.1 REYVOW works differently than other acute treatments for migraine.

  20. Show article details.

    BRIEF-EMA Says CHMP Recommends Approving Novo Nordisk's Rybelsus

    Reuters – 6:32 AM ET 01/31/2020

    European Medicines Agency: * CHMP RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR GIVLAARI. * CHMP ADOPTED POSITIVE OPINION FOR RYBELSUS FOR TREATMENT OF ADULTS WITH TYPE 2 DIABETES TO IMPROVE GLYCAEMIC CONTROL AS ADJUNCT TO DIET & EXERCISE. * NUBEQA RECEIVED A POSITIVE OPINION FOR THE TREATMENT OF PROSTATE CANCER FROM CHMP.

Page:

Today's and Upcoming Events

  • Apr
    23

    LLY to announce Q1 earnings (Confirmed)

Past Events (last 90 days)

  • Feb
    13

    LLY ex-Dividend for $0.74 on 02/13/2020

    • Announce Date: 12/16/2019
    • Record Date: 02/14/2020
    • Pay Date: 03/10/2020
  • Jan
    30

    LLY announced Q4 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.